在阿尔茨海默氏症疾病中的突触补偿性可塑性
Nishita Bhembre1, Calum Bonthron2, Patricio Opazo3,2
1Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, University of Queensland, Brisbane, Queensland 4072, Australia.
概括
神经元可以通过扩大现有的突触或再生新的突触来弥补阿尔茨海默病 (AD) 中的突触损失. 了解这些补偿机制是开发AD治疗的关键.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 激发性突触损失是与阿尔茨海默病 (AD) 相关的认知衰退的标志.
- 在AD中突触损失的机制已被理解,但补偿策略在很大程度上仍未被探索.
研究的目的:
- 审查AD中突触损失的潜在补偿机制.
- 突出纵向成像对于研究突触动态的重要性.
- 强调突触补偿在阿尔茨海默病治疗中的作用.
主要方法:
- 专注于显微镜方法监测树突,激发性突触的 postsynaptic 网站.
- 在固定组织成像上强调纵向树突性脊柱成像.
- 讨论关于突触损失和补偿的可视化技术.
主要成果:
- 提出了两个主要的补偿机制:生存突触的扩大和突触再生.
- 纵向成像为突触补偿的时间动态提供了关键的见解.
- 树突性脊柱形态变化可能表明补偿过程.
结论:
- 了解突触补偿和再生对于开发AD治疗至关重要.
- 针对补偿机制可能为AD的认知缺陷提供一种新的治疗策略.
- 对阿尔茨海默病突触可塑性的分子基础进行进一步的研究是有必要的.
相关概念视频
Neuroplasticity
390
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
390
Alzheimer's Disease: Overview
503
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503
Alzheimer's Disease: Treatment
211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
Long-term Potentiation
2.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.8K
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Role of Neurotransmitters in Memory
592
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
592


